Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 5/20 | 0.62 |
| ▸ | CA1 | P00915 | 5/20 | 0.62 |
| ▸ | CA2 | P00918 | 5/20 | 0.62 |
| ▸ | CA12 | O43570 | 4/20 | 0.62 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.62 |
| ▸ | CA3 | P07451 | 3/20 | 0.62 |
| ▸ | CA4 | P22748 | 3/20 | 0.62 |
| ▸ | CA6 | P23280 | 3/20 | 0.62 |
| ▸ | CA5A | P35218 | 3/20 | 0.62 |
| ▸ | CA7 | P43166 | 3/20 | 0.62 |
| ▸ | CA13 | Q8N1Q1 | 3/20 | 0.62 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.62 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.57 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | MMP8 | P22894 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1164063 | 0.80 | CA1 (0.72) | CA9CA1CA2CA12CA14 | |
| SCHEMBL30497605 | 0.79 | CA2 (0.66) | CA9CA1CA2CA12CA14 | |
| SCHEMBL7650160 | 0.77 | HTT (0.66) | CA9CA1CA2CA12CA14 | |
| SCHEMBL9463350 | 0.76 | CA2 (0.55) | CA9CA1CA2CA12CA14 | |
| SCHEMBL10687252 | 0.75 | CA9 (0.51) | CA9CA1CA2CA12CA14 | |
| Isobutane SCHEMBL18739954 | 0.74 | CA2 (0.84) | CA9CA1CA2CA12CA14 | |
| SCHEMBL18029396 | 0.74 | CA9 (0.64) | CA9CA1CA2CA12CA14 | |
| SCHEMBL27855209 | 0.74 | HSD17B10 (0.64) | CA9CA1CA2CA12CA14 | |
| SCHEMBL12989147 | 0.74 | SMN1; SMN2 (0.50) | CA1CA2VCAM1MMP1MMP2 | |
| SCHEMBL2936178 | 0.74 | SMN1; SMN2 (0.50) | CA9CA1CA2CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250082593-A1 | HALOALLYLAMINE SULFONE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | SYNTARA LIMITED (AU) | 2025-03-13 | — | — | US | disclosed |
| US-12178791-B2 | Haloallylamine sulfone derivative inhibitors of lysyl oxidases and uses thereof | SYNTARA LIMITED (AU) | 2024-12-31 | — | — | US | disclosed |
| EP-3829520-B1 | HALOALLYLAMINE SULFONE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | SYNTARA LTD (AU) | 2024-11-27 | — | — | EP | disclosed |
| CN-112533897-B | Halogenated allylamine sulfone derivative inhibitors of lysyl oxidase and uses thereof | 法玛西斯有限公司 | 2023-07-14 | — | — | CN | disclosed |
| CN-113666851-A | Optically pure chiral aminoacetal, preparation method and application thereof | 西北工业大学 | 2021-11-19 | — | — | CN | disclosed |
| US-20210353571-A1 | HALOALLYLAMINE SULFONE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | SYNTARA LIMITED (AU) | 2021-11-18 | — | — | US | disclosed |
| US-20210353571-A1 | HALOALLYLAMINE SULFONE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | SYNTARA LIMITED (AU) | 2021-11-18 | — | — | US | disclosed |
| EP-3829520-A1 | HALOALLYLAMINE SULFONE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | Pharmaxis Ltd. (AU) | 2021-06-09 | — | — | EP | disclosed |
| CN-112533897-A | Haloallylamine sulfone derivative inhibitors of lysyl oxidase and uses thereof | 法玛西斯有限公司 | 2021-03-19 | — | — | CN | disclosed |
| WO-2020024017-A1 | HALOALLYLAMINE SULFONE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | PHARMAXIS LTD. (AU) | 2020-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12178791-B2 | Haloallylamine sulfone derivative inhibitors of lysyl oxidases and uses thereof | LOX, DAO, LOXL1 | CA9 521/4885CA1 2442/4885CA2 1227/4885 |
| US-20250082593-A1 | HALOALLYLAMINE SULFONE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | LOX, DAO, LOXL1 | CA9 521/4885CA1 2442/4885CA2 1227/4885 |
| US-20210353571-A1 | HALOALLYLAMINE SULFONE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | LOX, DAO, LOXL1 | CA9 521/4885CA1 2442/4885CA2 1227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.